Postural Tachycardia Syndrome
49
7
20
22
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.1%
2 terminated out of 49 trials
91.7%
+5.2% vs benchmark
0%
0 trials in Phase 3/4
36%
8 of 22 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 22 completed trials
Clinical Trials (49)
POTS Adrenergic Ab (CIHR Aims #1&2)
Periaqueductal Gray-vagus Nerve Interface Malfunction Explain the Natural History With Its Numerous Co-morbidities?
Autoimmune Basis for Postural Tachycardia Syndrome
Autonomic Determinants of POTS - Pilot1
Autonomic Determinants of POTS - Pilot 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
The Impact of Improved Vagal Function on Periaqueductal Gray Connectivity
Modafinil and Cognitive Function in POTS
Aldosterone & Sodium Regulation in Postural Tachycardia Syndrome - Screening
Breathing Device in Postural Orthostatic Tachycardia Syndrome (POTS)
Autoimmune Basis for Postural Tachycardia Syndrome
Non-invasive Vagal Neurostimulation (nVNS) in Adolescents With Postural Orthostatic Tachycardia Syndrome (POTS)
Inappropriate Sinus Tachycardia Registry
Ultrasound Guided Stellate Ganglion Block in Postural Tachycardia Syndrome
POTS NET mRNA Functional Correlation With NET Activity
Sleep Actigraphy in Postural Tachycardia Syndrome (POTS)
Intravenous (IV) Saline and Exercise in Postural Tachycardia Syndrome (POTS)
Acute Salt Handling in Orthostatic Intolerance
fMRI in Postural Tachycardia Syndrome
Vagal Stimulation in POTS